Drug firm said its step-down wholly-owned subsidiary Vensun Pharmaceuticals, Inc., USA, and its partner Pharmaceutics International, Inc. (Pii), have received approval from the US health regulator for jointly developed Potassium Chloride extended-release tablets.
The approved product, used in treatment of patients with hypokalemia, is a generic version of Merck, Inc's Potassium Chloride extended-release tablets, it said.
Quoting IQVIA MAT data, Strides Pharma Science said the US market for Potassium Chloride extended-release tablets is approximately USD 240 million.
The product will be manufactured by Pii and will be marketed by Strides in the US market, it said.
Shares of Strides Pharma Science were trading 0.26 per cent higher at Rs 477.60 apiece on the BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)